PT  - JOURNAL ARTICLE
AU  - Lena M Lorenz
AU  - John Bradley
AU  - Joshua Yukich
AU  - Dennis Joram Massue
AU  - Zawadi Mageni Mboma
AU  - Olivier Pigeon
AU  - Jason Moore
AU  - Albert Kilian
AU  - Jo Lines
AU  - William Kisinza
AU  - Hans J Overgaard
AU  - Sarah J Moore
TI  - Comparative functional survival and equivalent annual cost of three long lasting insecticidal net (LLIN) products in Tanzania
AID  - 10.1101/19002212
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19002212
4099  - http://medrxiv.org/content/early/2019/08/01/19002212.short
4100  - http://medrxiv.org/content/early/2019/08/01/19002212.full
AB  - Almost 1.2 billion long-lasting insecticidal nets (LLINs) have been procured for malaria control. Institutional buyers often assume that World Health Organization (WHO) prequalified LLINs are functionally identical with a three-year lifespan. We measured the lifespans of three LLIN products, and calculated their cost-per-year of functional life, through a randomised double-blinded prospective evaluation among 3,420 study households in Tanzania using WHO-recommended methods. Primary outcome was LLIN functional survival (LLINs present in serviceable condition). Secondary outcomes were 1) bioefficacy and chemical content (residual insecticidal activity) and 2) protective efficacy for volunteers sleeping under LLINs (bite reduction and mosquitoes killed). LLIN median functional survival was significantly different: 2·0 years for Olyset, 2·5 years for PermaNet and 2·6 years for NetProtect. Functional survival was affected by accumulation of holes resulting in users discarding nets. Protective efficacy also significantly differed between products as they aged. The longer-lived nets were 20% cheaper than the shorter-lived product.Competing Interest StatementSarah Moore, William Kisinza, Olivier Pigeon and Jason Moore conduct product evaluations for a number of vector control product manufacturers. The other authors declare that they have no competing interests.Clinical TrialNot a clinical trialClinical Protocols https://bmcpublichealth.biomedcentral.com/track/pdf/10.1186/1471-2458-14-1266 Funding StatementThe research was made possible by the Research Council of Norway through the ABCDR Project no. 220757. Sarah Moore was funded by awards from IVCC and Notre Dame OPP1081737. Neither the sponsor nor the LLIN manufacturers had any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThe datasets supporting the conclusions of this article are available from the Norwegian Centre for Research Data (NSD) http://www.nsd.uib.no/nsd/english/index.html